Sectoral Asset Management Inc trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 47.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,917 shares of the biopharmaceutical company’s stock after selling 29,981 shares during the period. Regeneron Pharmaceuticals makes up approximately 1.9% of Sectoral Asset Management Inc’s holdings, making the stock its 26th biggest holding. Sectoral Asset Management Inc’s holdings in Regeneron Pharmaceuticals were worth $14,718,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Fieldpoint Private Securities LLC purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $130,000. Sterling Investment Advisors Ltd. raised its holdings in Regeneron Pharmaceuticals by 11.2% during the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 28 shares during the period. FNY Partners Fund LP raised its holdings in Regeneron Pharmaceuticals by 200.0% during the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 200 shares during the period. IFP Advisors Inc raised its holdings in Regeneron Pharmaceuticals by 33.2% during the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 96 shares during the period. Finally, Virtu KCG Holdings LLC purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $206,000. 66.67% of the stock is currently owned by institutional investors and hedge funds.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $475.00, for a total value of $712,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Charles A. Baker sold 2,000 shares of the firm’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $450.00, for a total value of $900,000.00. Following the completion of the sale, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by company insiders.

A number of analysts have weighed in on REGN shares. Canaccord Genuity set a $522.00 target price on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 14th. UBS reduced their target price on Regeneron Pharmaceuticals from $535.00 to $500.00 and set a “buy” rating on the stock in a research note on Thursday, September 21st. Credit Suisse Group reiterated a “buy” rating and issued a $485.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, September 11th. Citigroup reiterated a “buy” rating and issued a $575.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, September 7th. Finally, Guggenheim reiterated a “buy” rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $467.84.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at $373.61 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $340.09 and a 12-month high of $543.55. The firm has a market capitalization of $40,303.59, a PE ratio of 32.48, a P/E/G ratio of 1.47 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping the consensus estimate of $3.83 by $0.16. The business had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company’s quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter last year, the company earned $3.13 earnings per share. equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Holdings Trimmed by Sectoral Asset Management Inc” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/12/08/regeneron-pharmaceuticals-inc-regn-holdings-trimmed-by-sectoral-asset-management-inc.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.